Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices 65641 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27063 Filed 10–25–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Risk Communication Advisory 

Committee; Amendment of Notice 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

The Food and Drug Administration 

(FDA) is announcing an amendment to 

the notice of meeting of the Risk 

Communication Advisory Committee. 

This meeting was announced in the 

Federal Register of September 20, 2010 

(75 FR 57279). The amendment is being 

made to reflect a change in the Agenda 

portion of the document. There are no 

other changes. 

FOR FURTHER INFORMATION CONTACT: Lee 

L. Zwanziger, Office of Policy, Planning 

and Budget, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 3278, Silver Spring, 

MD 20993, 301–796–9151, FAX: 301– 

847–8611, e-mail: RCAC@fda.hhs.gov, 

or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington, DC 

area), code 8732112560. Please call the 

Information Line for up-to-date 

information on this meeting. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of September 20, 2010, 

FDA announced that a meeting of the 

Risk Communication Advisory 

Committee would be held on November 

8 and 9, 2010. On page 57280, in the 

first column, the Agenda portion of the 

document is changed to read as follows: 

Agenda: On November 8 and 9, 2010, 

the Committee will hear and discuss 

developments in FDA’s ongoing 

communications programs, such as 

FDA’s Strategic Plan for Risk 

Communication, FDA’s Transparency 

Initiative, foodborne outbreaks and 

related recall communications, and the 

challenges of effectively communicating 

with patients and caregivers about 

appropriate use of medical devices 

when a patient is prescribed a medical 

device for home use. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to the advisory committees. 

Dated: October 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27060 Filed 10–25–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Tobacco Products Scientific Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Tobacco 

Products Scientific Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 18, 2010, from 1 p.m. 

until 5 p.m. 

Location: FDA White Oak Conference 

Center, 10903 New Hampshire Ave., 

Bldg. 31, rm. 1503, Silver Spring, MD 

20993–0002. Information regarding 

special accommodations due to a 

disability, visitor parking, and 

transportation may be accessed at: 

http://www.fda.gov/ 

AdvisoryCommittees/default.htm; under 

the heading ‘‘Resources for You’’ click 

on ‘‘White Oak Conference Center 

Parking and Transportation Information 

for FDA Advisory Committee Meetings.’’ 

Contact Person: Caryn Cohen, Office 

of Science, Center for Tobacco Products, 

Food and Drug Administration, 9200 

Corporate Blvd., Rockville, MD 20850, 

1–877–287–1373 (choose Option 4), 

e-mail: TPSAC@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732110002. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the Agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On November 18, 2010, the 

committee will (1) Receive an update on 

the Menthol Report Subcommittee and 

(2) receive and discuss presentations 

regarding the data requested by the 

committee at the March 30 and 31, 

2010, meeting of the Tobacco Products 

Scientific Advisory Committee. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 9, 2010. 

Oral presentations from the public will 

be scheduled between approximately 3 

p.m. and 4 p.m. on November 18, 2010. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

November 1, 2010. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by November 2, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Caryn Cohen 


emcdonald on DSK2BSOYB1PROD with NOTICES
65642 Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27008 Filed 10–25–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; HIV/ 

AIDS Behavioral Treatment Intervention and 

Services Development-Member Conflict. 

Date: November 12, 2010. 

Time: 9:30 a.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. (Telephone 

Conference Call) 

Contact Person: Enid Light, PhD, Scientific 

Review Officer, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center, 6001 

Executive Boulevard, Room 6132, MSC 9608, 

Bethesda, MD 20852, 301–443–3599, 

elight@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: October 18, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–26959 Filed 10–25–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Amended Notice 

of Meeting 

Notice is hereby given of a change in 

the meeting of the Council of Councils, 

November 8, 2010, 9 a.m. to November 

8, 2010, 3 p.m., National Institutes of 

Health, Building 31, 31 Center Drive, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

September 30, 2010, 75 FR 60465. 

This Federal Register Notice is 

amended to add a Closed Session from 

12:15 p.m. to 12:45 p.m. on November 

8, 2010. 

The meeting is partially closed to the 

public. 

Dated: October 20, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27051 Filed 10–25–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Listing of Members of the 

National Centers for Disease Control 

and Prevention’s 2010 Performance 

Review Board (PRB) 

AGENCY: The Centers for Disease Control 

and Prevention (CDC), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) 

announces the persons who will serve 

on the CDC’s 2010 Performance Review 

Board. This action is being taken in 

accordance with Title 5, U.S.C., 

4314(c)(4), which requires that members 

of performance review boards be 

appointed in a manner to ensure 

consistency, stability, and objectivity in 

performance appraisals and requires 

that notice of the appointment of an 

individual to serve as a member be 

published in the Federal Register. 

The following persons will serve on 

the CDC Performance Review Board, 

which is responsible for making 

recommendations on performance 

appraisal ratings, pay adjustments, and 

performance awards for CDC’s Senior 

Executive Service (SES) members: 

Kevin Fenton (Co-Chair), Lynn Austin 

(Co-Chair), Ed Hunter, Rima Khabbaz, 

Crayton Lankford, Carolyn Black, 

Christine Branche, Anne Haddix, 

Barbara Harris, Jim Seligman, Walter 

Harris, Hazel Dean, Bill Porter. 

For further information about the CDC 

Performance Review Board, contact the 

Centers for Disease Control and 

Prevention, Human Capital Management 

Office, Human Capital Planning Branch, 

1600 Clifton Road, NE., MS E–50, 

Atlanta, GA 30333. Telephone (404) 

498–6709 (not a toll free number). 

Dated: October 20, 2010. 

Tanja Popovic, 

Deputy Associate Director for Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2010–26999 Filed 10–25–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0511] 

Withdrawal of Approval of New Animal 

Drug Applications; Aklomide; 

Levamisole Hydrochloride; Nitromide 

and Sulfanitran 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is withdrawing 

approval of eight new animal drug 

applications (NADAs). In a final rule 

published elsewhere in this issue of the 

Federal Register, FDA is amending the 

animal drug regulations to remove 

portions reflecting approval of these 

NADAs. 

DATES: Withdrawal of approval is 

effective November 5, 2010. 

FOR FURTHER INFORMATION CONTACT: John 

Bartkowiak, Center for Veterinary 

Medicine (HFV–212), Food and Drug 

Administration, 7519 Standish Pl., 

Rockville, MD 20855, 240–276–9079, 

e-mail: john.bartkowiak@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Fort 

Dodge Animal Health, a Division of 

Wyeth Holdings, a Wholly Owned 

Subsidiary of Pfizer, Inc., 235 East 42d 


emcdonald on DSK2BSOYB1PROD with NOTICES